Bioresorbable Stents

Bioresorbable Stents

Global Bioresorbable Stents Market to Reach US$1.2 Billion by 2030

The global market for Bioresorbable Stents estimated at US$554.4 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2023-2030. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$905.2 Million by the end of the analysis period. Growth in the Metal-based Bioresorbable Stents segment is estimated at 10.2% CAGR over the analysis period.

Global Bioresorbable Stents Market - Key Trends & Drivers Summarized

Bioresorbable stents, also known as bioresorbable vascular scaffolds (BVS), represent a significant advancement in interventional cardiology. These stents are designed to provide temporary support to the artery after a procedure, gradually dissolving over time and leaving behind a natural vessel. Unlike traditional metal stents, which remain permanently in the body, bioresorbable stents are composed of materials like polylactic acid (PLA) that naturally break down and are absorbed by the body. This temporary nature reduces the long-term risks associated with permanent implants, such as chronic inflammation and late-stage thrombosis. Clinical trials have demonstrated the efficacy of bioresorbable stents in treating coronary artery disease, showing comparable outcomes to metallic stents with the added benefit of restoring the vessel`s natural function and flexibility over time.

The development of bioresorbable stents has been propelled by extensive research and technological innovations. These stents are engineered to provide the necessary mechanical support to the artery during the critical healing period post-angioplasty. Over time, the stent gradually degrades, reducing the risk of long-term complications. Additionally, bioresorbable stents are often coated with antiproliferative drugs to further prevent restenosis, or re-narrowing of the artery. This dual function of providing mechanical support and drug delivery enhances the therapeutic outcomes for patients. Furthermore, the use of advanced imaging techniques and precision engineering has improved the deployment and efficacy of these stents, making them a viable option for a broader range of patients and clinical scenarios.

The growth in the bioresorbable stents market is driven by several factors. Firstly, there is an increasing prevalence of cardiovascular diseases globally, particularly coronary artery disease, which necessitates effective and innovative treatment options. Secondly, the rising demand for minimally invasive procedures among patients and healthcare providers is fueling the adoption of bioresorbable stents. These stents offer a promising alternative to traditional methods, aligning with the trend towards less invasive interventions. Thirdly, technological advancements in biomaterials and stent design are enhancing the performance and safety profile of bioresorbable stents, making them more attractive to clinicians. Lastly, the growing awareness and acceptance of these stents among patients, coupled with favorable reimbursement policies in several regions, are further boosting market growth. The confluence of these factors underscores the expanding role of bioresorbable stents in modern cardiovascular treatment paradigms.

Select Competitors (Total 25 Featured) -

• Abbott Laboratories, Inc.
• Boston Scientific Corporation
• Biotronik SE & Co. KG
• Eurocor GmbH
• Biosensors International Group Ltd.
• Elixir Medical Corporation
• InSitu Technologies, Inc.
• Kyoto Medical Planning Co., Ltd.
• Medinol Ltd.
• Lepu Medical Technology (Beijing) Co., Ltd.
• Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
• Meril Life Sciences Pvt., Ltd.
• Arterial Remodeling Technologies SA
• iVascular S.L.U
• Endocor GmbH

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.